Αποτελέσματα Αναζήτησης
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
1 Μαΐ 2018 · Dose-Dense AC is repeated every 2 weeks or 14 days. This is known as one Cycle and is repeated for a total of 4 cycles. During TH treatment, paclitaxel is given every 14 days and trastuzumab is given once a week for the first eight weeks. Then, trastuzumab is given alone every 21 days for 44 weeks.
Treatment overview. This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
DOXOrubicin and cyclophosphamide are administered once every 21 days for four cycles (one cycle = 21 days) followed by PACLitaxel administered on day 1, 8 and 15 every 21 days for 4 cycles (one cycle = 21 days) unless disease progression or unacceptable toxicity develops.
The trial compared 4 cycles of 3 weekly AC (doxorubicin and cyclophosphamide) with 6 cycles of 4 weekly CMF (cyclophosphamide, methotrexate and fluorouracil) in patients with breast cancer non-responsive to tamoxifen. The study also compared the sequential use of both AC and CMF treatment to AC alone.
8 Οκτ 2014 · Adjuvant therapy aids surgery in effecting cure of breast cancer. Adjuvant treatments for breast cancer can include chemotherapy, hormonal therapy, human epidermal growth factor receptor (HER2)–directed therapies, and radiation.
11 Απρ 2024 · Sequential Adriamycin-cyclophosphamide therapy with paclitaxel or docetaxel (AC-T) was declared by a 2015 review to likely be the most effective treatment regimen of early-stage breast cancer regardless of hormone status.
